Review article: A critical comparison of drug therapies in currently used therapeutic strategies for variceal haemorrhage

Alimentary Pharmacology and Therapeutics

Volumn 20, Issue SUPPL. 3, 2004, Pages 18-22

  Nevens, F ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

OCTREOTIDE; PLACEBO; SOMATOSTATIN; SOMATOSTATIN DERIVATIVE; TERLIPRESSIN; VAPREOTIDE; VASOACTIVE AGENT;

AZYGOS VEIN; BLOOD FLOW VELOCITY; BOLUS INJECTION; CLINICAL PROTOCOL; CLINICAL TRIAL; CONFERENCE PAPER; CONTINUOUS INFUSION; DISEASE SEVERITY; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG EFFICACY; DRUG POTENCY; DRUG SAFETY; DRUG SCREENING; ENDOSCOPIC SCLEROTHERAPY; ESOPHAGUS VARICES BLEEDING; HUMAN; ISCHEMIA; KIDNEY FUNCTION; LIVER CIRRHOSIS; MORTALITY; OUTCOMES RESEARCH; PORTAL VEIN BLOOD PRESSURE; PRIORITY JOURNAL; SURVIVAL RATE; VENOUS PRESSURE;

ESOPHAGEAL AND GASTRIC VARICES; GASTROINTESTINAL AGENTS; GASTROINTESTINAL HEMORRHAGE; HUMANS; LYSINE VASOPRESSIN; OCTREOTIDE; SOMATOSTATIN; VASOCONSTRICTOR AGENTS;

EID: 4644228361     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2004.02110.x     Document Type: Conference Paper

References (42)

1. D'Amico G, Luca A. Natural history. Clinical-haemodynamic correlations. Prediction of the risk of bleeding. Baillières Clin Gastroenterol 1997; 11: 243-56.
2. Burroughs AK. The natural history of varices. J Hepatol 1993; 17 (Suppl. 2): S10-3.
3. McCormick PA, O'Keefe C. Improving prognosis following a first variceal haemorrhage over four decades. Gut 2001; 49: 682-5.
4. Bleichner G, Boulanger R, Squara P, Sollet JP. Frequency of infections in cirrhotic patients presenting with acute gastrointestinal haemorrhage. Br J Surg 1986; 73: 724-46.
5. Bernard B, Grange JD, Khac EN, et al. Antibiotic prophylaxis for the prevention of bacterial infections in cirrhotic patients with gastrointestinal bleeding: a meta-analysis. Hepatology 1999; 29: 1655-61.
6. de Franchis R, Pascal JP, Ancona E, et al. Definitions, methodology and therapeutic strategies in portal hypertension. J Hepatol 1992; 15: 256-61.
7. Mitchell K, Theodossi A, Williams R. Endoscopy in patients with portal hypertension and upper gastrointestinal bleeding. In: Williams, R, Westaby, D, eds. Variceal Bleeding. London: Pitman 1982, 62-7.
8. de Franchis R, Primignani M. Endoscopic treatments for portal hypertension. Semin Liver Dis 1999; 19: 439-55.
9. Banares R, Albillos A, Rincon D, et al. Endoscopic treatment versus endoscopic plus pharmacologic treatment for acute variceal bleeding: a meta-analysis. Hepatology 2002; 35: 609-15.
10. Avgerinos A, Nevens F, Raptis S, Fevery J. Early administration of somatostatin and efficacy of sclerotherapy in acute oesophageal variceal bleeds: the European Acute Bleeding Oesophageal Variceal Episodes (ABOVE) randomized trial. Lancet 1997; 350: 1495-9.
11. Cales P, Masliah C, Bernard B, et al. Early administration of vapreotide for variceal bleeding in patients with cirrhosis. French Club for Study Portal Hypertension N Engl J Med 2001; 344: 23-8.
12. D'Amico G, Pietrosi G, Tarantino I, Pagliaro L. Emergency sclerotherapy versus vasoactive drugs for variceal bleeding in cirrhosis: a Cochrane meta-analysis. Gastroenterology 2003; 124: 1277-91.
13. Garcia-Pagan JC, Escorsell A, Moitinho E, Bosch J. Influence of pharmacological agents on portal hemodynamics: basis for its use in the treatment of portal hypertension. Sem Liver Dis 1999; 19: 427-38.
14. Nevens F, Van Steenbergen W, Yap SH, Fevery J. Assessment of variceal pressure by continuous non-invasive endoscopic registration: a placebo controlled evaluation of the effect of terlipressin and octreotide. Gut 1996; 38: 129-34.
15. Moreau R, Soubrane O, Hadengue A, et al. Effects hémodynamiques de l'administration de terlipressine seule ou associée à la nitroglycérine chez les malades atteints de cirrhose. Gastroenterol Clin Biol 1992; 16: 680-6.
16. Escorsell A, Bandi JC, Moitinho E, et al. Time profile of the hemodynamic effects of terlipressin in portal hypertension. J Hepatol 1997; 26: 621-7.
17. Walker S, Stiehl A, Raedsch R, Kommerell B. Terlipressin in bleeding oesophageal varices. A placebo controlled double-blind study. Hepatology 1986; 6: 112-5.
18. Freeman JG, Cobden I, Record CO. Placebo-controlled trial of terlipressin (terlipressin) in the management of acute variceal bleeding. J Clin Gastroenterol 1989; 11: 58-60.
19. Soderlund C, Magnusson I, Torngren S, Lundell L. Terlipressin (triglycyl-lysine vasopressin) controls acute bleeding oesophageal varices. A double-blind, randomized, placebo-controlled trial. Scand J Gastroenterol 1990; 25: 622-30.
20. Levacher S, Letoumelin P, Pateron D, et al. Early administration of terlipressin plus glyceryl-trinitrate to control active upper gastrointestinal bleeding in cirrhotic patients. Lancet 1995; 346: 865-8.
21. Moreau R, Durand F, Poynard T, et al. Terlipressin in patients with cirrhosis and type 1 hepatorenal syndrome: a retrospective multicenter study. Gastroenterology 2002; 122: 923-30.
22. Feu F, Ruiz Del Arbol L, Banares R, et al. Double-blind randomized controlled trial comparing terlipressin and somatostatin for acute variceal hemorrhage. Gastroenterology 1996; 111: 1291-9.
23. Cirera I, Feu F, Luca A, et al. Effects of bolus injections and continuous infusions of somatostatin and placebo in patients with cirrhosis: a double-blind hemodynamic investigation. Hepatology 1995; 22: 106-11.
24. Nevens F, Sprengers D, Fevery J. The effect of different doses of a bolus injection of somatostatin combined with a slow on transmural oesophageal variceal pressure in patients with cirrhosis. J Hepatol 1994; 20: 27-31.
25. Villanueva C, Ortiz J, Minana J, et al. Somatostatin treatment and risk stratification by continuous portal pressure monitoring during acute variceal bleeding. Gastroenterology 2001; 121: 110-7.
26. Burroughs AK, McCormick PA, Hughes MD, et al. Randomized double-blind trial, placebo-controlled trial of somatostatin for variceal bleeding. Emergency control and prevention of early variceal rebleeding. Gastroenterology 1990; 99: 1388-95.
27. Valenzuela JE, Schubert T, Fogel MR, et al. A multicenter randomized double-blind trial of somatostatin in the management of acute hemorrhage from esophageal varices. Hepatology 1989; 10: 958-61.
28. Gotzsche PC, Gjorup I, Bonnén H, et al. Somatostatin vs placebo in bleeding oesophageal varices: randomized trial and meta-analysis. BMJ 1995; 310: 1495-8.
29. Moitinho E, Planas R, Banares R, et al. Multicenter randomized controlled trial comparing different schedules of somatostatin in the treatment of acute variceal bleeding. J Hepatol 2001; 35: 712-8.
30. Ottensen LH, Flyvberg A, Jakobsen P, Bendtsen F. The pharmacokinetics of octreotide in cirrhosis and in healthy man. J Hepatol 1997; 26: 1018-25.
31. Jenkins SA, Nott DM, Baxter JN. Pharmacokinetics of octreotide in patients with cirrhosis and portal hypertension; relationship between the plasma levels of the analogue and the magnitude and duration of the reduction in corrected wedged hepatic venous pressure. HPB Surg 1998; 11: 13-21.
32. Zironi G, Rossi C, Siringo S, et al. Short- and long-term hemodynamic response to octreotide in portal hypertensive patients: a double-blind, controlled study. Liver 1996; 16: 225-34.
33. Moller S, Brinch K, Henriksen JH, Becker U. Effect of octreotide on systemic, central, and splanchnic haemodynamics in cirrhosis. J Hepatol 1997; 26: 1026-33.
34. Escorsell A, Bandi JC, Andreu V, et al. Desensitization to the effects of intravenous octreotide in cirrhotic patients with portal hypertension. Gastroenterology 2000; 120: 161-9.
35. McCormick PA, Dick R, Graffeo M, et al. The effect of non-protein liquid meals on the hepatic venous pressure gradient in patients with cirrhosis. J Hepatol 1990; 11: 221-5.
36. Albillos A, Rossi I, Iborra J, et al. Octreotide prevents post-prandial splanchnic hyperemia in patients with portal hypertension. J Hepatol 1994; 21: 88-94.
37. Primignani M, Carpinelli L, Vazzoler MC, et al. Short term effect of octreotide on intraoesophageal variceal pressure: a double-blind placebo-controlled study. Eur J Gastroenterol Hepatol 1994; 6: 1027-31.
38. Burroughs AK. Double blind RCT of 5 day octreotide versus placebo, associated with sclerotherapy for trial/failures (Abstract). Hepatology 1996; 24: 352A.
39. Besson I, Ingrand P, Person B, et al. Sclerotherapy with or without octreotide for acute variceal bleeding. N Engl J Med 1995; 333: 555-60.
40. Sung JJY, Chung SCS, Yung MY, et al. Prospective randomized study of effect of octreotide on rebleeding from oesophageal varices after endoscopic ligation. Lancet 1995; 346: 1666-9.
41. Zuberi BF, Baloch Q. Comparison of endoscopic variceal sclerotherapy alone and in combination with octreotide in controlling acute variceal hemorrhage and early rebleeding in patients with low-risk cirrhosis. Am J Gastroenterol 2000; 95: 768-71.
42. Cales P, Masliah C, Bernard B, et al. Early administration of vapreotide for variceal bleeding in patients with cirrhosis. N Engl J Med 2001; 344: 23-8.